Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.60 |
| ▸ | CTSB | P07858 | 6/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 3/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7186825 | 0.88 | CTSL (0.61) | CTSLCTSBTDP1CAPN1MAOB | |
| SCHEMBL7186830 | 0.88 | CTSL (0.61) | CTSLCTSBTDP1CAPN1MAOB | |
| SCHEMBL498959 | 0.87 | NR1H4 (0.59) | CTSLCTSBTDP1CAPN1CHRNA7 | |
| SCHEMBL498780 | 0.86 | MAPT (0.46) | CTSLCTSBTDP1TNFRSF1A | |
| SCHEMBL499474 | 0.83 | AR (0.58) | MAOBCHRNA7 | |
| SCHEMBL7186683 | 0.82 | CAPN1 (0.56) | CTSLCTSBTDP1CAPN1MAOB | |
| SCHEMBL7186678 | 0.82 | CAPN1 (0.56) | CTSLCTSBTDP1CAPN1MAOB | |
| SCHEMBL7192416 | 0.81 | PTPN1 (0.56) | CTSLCTSBTDP1CAPN1MAOB | |
| SCHEMBL7192414 | 0.81 | PTPN1 (0.56) | CTSLCTSBTDP1CAPN1MAOB | |
| SCHEMBL498877 | 0.80 | MAPT (0.47) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | claimed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | claimed |
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | PSEN1, BACE1, PSEN2 | CTSL 2649/4885CTSB 734/4885TDP1 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.